SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2006, for Spherix Incorporated. The Company operates through two primary segments: InfoSpherix, which provides contact center and reservation services (primarily for government entities), and BioSpherix, which develops proprietary health products, notably tagatose (branded as Naturlose). On January 1, 2006, the InfoSpherix division was transferred to a wholly-owned subsidiary, InfoSpherix Incorporated.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2006 | Nine Months Ended Sept 30, 2006 |
|---|---|---|
| Revenue | $7,252,642 | $20,757,096 |
| Net Income (Loss) | $(9,540) | $(303,968) |
| Operating Income (Loss) | $(13,810) | $(311,088) |
| Cash and Cash Equivalents | $5,757,468 (as of Sept 30, 2006) | |
| Working Capital | ~$7.0 million (as of Sept 30, 2006) | |
| Debt (Bank Line of Credit) | $0 (Outstanding balance) | |
| Net Cash Provided by Operating Activities | $1,070,394 (Nine months) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 8% for both the three-month and nine-month periods compared to 2005, driven primarily by a new contract with the Pennsylvania Department of Natural Resources.
- Profitability: The Company reported a net loss for the current periods, contrasting with a net income of $284,938 for the three months ended September 30, 2005. The nine-month loss narrowed significantly from $(560,458) in 2005 to $(303,968) in 2006.
- Expense Increases: Research and Development (R&D) expenses surged to $722,654 for the nine months (vs. $211,806 in 2005) due to Phase 3 clinical trial preparations for Naturlose. Selling, General, and Administrative (SG&A) expenses rose 12% year-over-year, largely due to legal fees associated with a lawsuit against the USDA.
- Liquidity Improvement: Cash and cash equivalents more than doubled from $2.67 million at year-end 2005 to $5.76 million, fueled by $3.1 million in proceeds from stock issuances and warrant exercises.
Guidance, Outlook, and Risks
- Legal Settlement: In October 2006, the Company agreed to a $6 million settlement to resolve a dispute with the U.S. Department of Agriculture regarding the National Recreation Reservation Service (NRRS) contract. The Company's National Park Service contract is set to expire on December 31, 2006, creating a need to replace this revenue stream or reduce costs.
- BioSpherix Outlook: The Phase 3 clinical trial for Naturlose (diabetes treatment) is expected to begin recruiting patients by April 2007, with completion potentially within two years. The Company retains rights to non-food uses of tagatose but receives no significant royalties from food/beverage licensee Arla Foods, which has halted production.
- Capital Resources: The Company maintains a $1.5 million line of credit for its InfoSpherix subsidiary, which is currently unutilized. Future funding for BioSpherix R&D will rely on existing cash, potential partnerships, or additional stock issuances under the Standby Equity Distribution Agreement (SEDA), which has $1.7 million remaining capacity.
- Risks: Key risks include the expiration of the National Park Service contract, the uncertainty of clinical trial outcomes for Naturlose, and the dependency on government contracts for the majority of revenue.
Investor Verification Checklist
- Verify the status of the $6 million USDA settlement and the specific terms regarding the NRRS contract dispute.
- Confirm the timeline and budget for the Phase 3 clinical trial for Naturlose, given the significant increase in R&D spend.
- Assess the Company's strategy to replace the $3.4 million in revenue from the expiring National Park Service contract by December 31, 2006.
- Review the covenants on the InfoSpherix line of credit to understand restrictions on cash transfers to the parent company.
- Monitor the remaining capacity and utilization of the Standby Equity Distribution Agreement (SEDA) for future capital needs.